Answers are grounded in this paper and cite their sources.
Subarachnoid hemorrhage (SAH) remains a devastating neurological condition with high mortality and morbidity, largely due to secondary brain injury mechanisms such as early brain injury (EBI) and secondary white matter injury (SWMI). Conventional surgical and medical interventions have not been sufficient to prevent long-term disability, prompting investigation into novel regenerative strategies. We conducted a narrative review of preclinical and limited clinical evidence on stem cell– and extracellular vesicle/exosome–based therapies for SAH, with emphasis on MSCs and their derivatives. PubMed/MEDLINE and Embase were searched between February and March 2025 for studies examining mechanisms, therapeutic targets, dosing, timing, and routes of administration. Stem cell–based therapies, particularly MSCs and their exosomes, have shown the ability to attenuate neuroinflammation, oxidative stress, excitotoxicity, and BBB disruption. Key mechanisms include modulation of the HMGB1/TLR4/NF-κB axis, polarization of microglia toward an anti-inflammatory phenotype, and secretion of trophic factors such as TSG-6, BDNF, and NT-3. Preclinical studies demonstrate improvements in neurological function, cognitive outcomes, and histological preservation across multiple SAH models. Exosome delivery of microRNAs (e.g., miR-129-5p, miR-193b-3p) has emerged as a potent cell-free strategy. Benefits have been reported after both early and delayed administration; however, differences in experimental models, therapeutic products, dosing methods, routes of administration, and outcome measures prevent direct cross-study comparisons and preclude identification of an optimal treatment window. MSC-derived therapies, hold significant promise for mitigating secondary injury and improving outcomes after SAH. Despite this promise, significant translational challenges concerning optimal dosing, delivery methods, and long-term safety must still be addressed. The path to clinical use requires rigorous validation in large animal models before advancing to human trials. Such validation may support the future clinical development of stem cell-based therapies for SAH.
No takes yet. Share an insight, caveat, or question.
Hamad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: